Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science

16:05 EST 28 Nov 2018 | Businesswire
This article has expired, however you can still download the PDF.
Aimmune Therapeutics, Inc. (Nasdaq:AIMT), a biopharmaceutical company developing treatments for potentially life-threatening food allergies, today announced the closing of the $98 million equity investment by Nestlé Health Scie...

Other Sources for this Article

Laura Hansen, Ph.D.
(650) 396-3814

Alison Marquiss
(650) 376-5583


More From BioPortfolio on "Aimmune Therapeutics Announces Closing of $98 Million Investment by Nestlé Health Science"

Quick Search

Relevant Topics

Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Food is any substance consumed to provide nutritional support for the body. It is usually of plant or animal origin, and contains essential nutrients, such as carbohydrates, fats, proteins, vitamins, or minerals. The substance is ingested by an organism ...

The term allergy is used to describe a response, within the body, to a substance, which is not necessarily harmful in itself, but results in an immune response and a reaction that causes symptoms and disease in a predisposed person, which in turn can cau...